An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.